Apolipoprotein B-100 is the 4,536-residue protein of hepatic VLDL and its LDL descendant: one ApoB-100 per particle, wrapped around the lipid at birth in the liver and never exchanged. It is the LDL receptor's ligand (clearance), PCSK9's handle (degradation of that receptor), and lipidology's counting unit — one ApoB, one atherogenic particle, which is why ApoB measurement summarizes what LDL cholesterol only estimates. Its mutational spectrum runs from familial hypercholesterolemia (defective receptor binding) to hypobetalipoproteinemia (truncations).
Gene
APOB (2p24.1) — one of the longest human genes
Family
Non-exchangeable apolipoproteins
Location
VLDL, IDL, LDL, Lp(a) particle surfaces in plasma
Structure
550 kDa single chain in five α-helical/Pentapartite domains
The Pentapartite model (five domains of alternating amphipathic α-helix and β-sheet) encircles the particle; compaction as VLDL shrinks to LDL buries and reveals receptor-active regions.
The receptor-binding region sits in the N-terminal third; R3500Q (FDB) and R3500W mutations abolish LDL-receptor affinity — familial defective ApoB-100.
In Lp(a), ApoB-100's C-terminal lysine ties to apo(a)'s kringle-IV chain — the atherothrombotic particle's disulfide knot.
Function
Assembly and secretion: ApoB's lipidation by MTP in the hepatocyte is the rate-setting step of VLDL production — the target of lomitapide and of the old MTP-loss disease (abetalipoproteinemia).
Clearance ligand: LDL-receptor binding of ApoB-100 removes LDL from plasma; PCSK9's binding to the receptor hastens its lysosomal destruction — the loop evolocumab/alirocumab cut.
Arterial retention: ApoB's basic patches bind arterial proteoglycans — the retention step that starts atherosclerosis.
Regulation
Co- and post-translational MTP lipidation decides degradation (proteasomal if under-lipidated) versus secretion — the quality gate of VLDL assembly; see apolipoprotein family context.
LDL-receptor activity (statins up-regulate via SREBP2) sets ApoB-particle lifetime — the drugs work on the receptor, not the protein.
Insulin suppresses hepatic ApoB output — diabetes's atherogenic dyslipidemia is partly the loss of that brake.
Interactions
One-ApoB-per-particle stoichiometry is what makes ApoB a particle counter — the lipid cargo varies, the protein does not.
With Lp(a)'s apo(a): genetically determined kringle copies set Lp(a) mass — the strongest single inherited cardiovascular risk factor.
With the immune system: oxidised ApoB epitopes drive LDL's immunogenicity in the plaque.
Clinical Relevance
Diagnostics: ApoB as the one-number atherogenic summary — guideline-recognized especially in hypertriglyceridemia where LDL-C undercounts.
Genetic: familial defective ApoB-100 (R3500), familial hypobetalipoproteinemia (truncations), abetalipoproteinemia (MTP) — the recessive absorption failure with acanthocytes and fat-soluble-vitamin loss, see vitamin A.
Therapy targets: mipomersen/olezarsen-class ApoB-synthesis inhibitors, lomitapide (MTP), PCSK9 inhibitors on the receptor side — each step of ApoB's life in the circulation now has a drug or candidate.